Viking Therapeutics, Inc. 8-K

What Happened
Viking Therapeutics, Inc. (VKTX) filed an 8-K on May 26, 2026 reporting the results of its May 19, 2026 Annual Meeting of Stockholders. Of 115,893,943 shares outstanding as of the March 20, 2026 record date, 80,089,532 shares (≈69.1%) were represented, establishing a quorum. Stockholders elected J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve until the 2029 annual meeting, ratified CBIZ CPAs P.C. as the company’s independent registered public accounting firm for fiscal year 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.

Key Details

• Record date and quorum: 115,893,943 shares outstanding (Mar 20, 2026); 80,089,532 shares represented (69.1%).
• Director elections (Class II, term to 2029): J. Matthew Singleton — 28,648,459 votes For; 14,562,012 Votes Withheld; 36,879,061 Broker Non-Votes. S. Kathryn Rouan, Ph.D. — 21,960,203 votes For; 21,250,268 Votes Withheld; 36,879,061 Broker Non-Votes.
• Auditor ratification: CBIZ CPAs P.C. ratified as independent registered public accounting firm for year ending Dec 31, 2026 — 78,368,957 For; 1,241,969 Against; 478,606 Abstentions.
• Advisory executive compensation vote: 30,045,938 For; 12,763,135 Against; 401,396 Abstentions; 36,879,063 Broker Non-Votes.

Why It Matters
These results confirm board continuity with two directors elected through 2029, formalize the company’s auditor for 2026 (important for audit continuity and financial reporting), and show majority support for executive compensation on an advisory basis. The advisory nature of the pay vote means it is non-binding, but the outcome signals shareholder sentiment on executive pay. Investors may note the sizable broker non-votes on director and compensation items, which reflect shares held in street name where brokers did not vote on non-routine matters.